Latest Market News

Pacgold’s initial drilling at the St George Project in Queensland confirms multiple thick zones of high-grade antimony, revealing a province-scale opportunity spanning over 20km. With further assays pending, the project positions Pacgold strategically in a critical and constrained antimony market.

State Street Global Advisors has announced estimated distributions for its suite of SPDR ETFs for the period ending December 31, 2025, providing investors with key income expectations across Australian and international equities as well as fixed income funds.

Saunders International has landed a $10.4 million contract to build new water storage infrastructure in South West Sydney, reinforcing its foothold in the growing water infrastructure sector.

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Blue Star Helium Limited has raised up to A$8.2 million through a placement and rights issue to fund production scale-up and further drilling at its Galactica helium project in North America.

Gratifii Limited is set to transform its digital marketing and engagement capabilities through the acquisition of New Zealand’s Mosh Digital and the Future Pass digital wallet platform, backed by a $2.5 million capital raise.

Silver Mines Limited reports promising results from a recent drilling program at its Tuena Project, revealing significant gold and base metal mineralisation along a key fault corridor in New South Wales.

Regal Investment Fund has announced an estimated ordinary dividend of AUD 0.12 per unit for the half-year ending December 2025, alongside a full Dividend Reinvestment Plan available to eligible investors.

Reece Limited has increased its on-market share buyback target by $50 million, raising the total to $85 million as part of its disciplined capital management strategy.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Finbar Group has conditionally acquired a prime South Perth site for $16.5 million, aiming to launch a $350 million apartment development by 2028 and boosting its pipeline to over $1.6 billion.